Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL

Results of a prospective study (ALL MRD2002 Study)

Koji Nagafuji, Toshihiro Miyamoto, Tetsuya Eto, Tomohiko Kamimura, Shuichi Taniguchi, Takashi Okamura, Eiichi Ohtsuka, Takashi Yoshida, Masakazu Higuchi, Goichi Yoshimoto, Tomoaki Fujisaki, Yasunobu Abe, Yasushi Takamatsu, Shouhei Yokota, Koichi Akashi, Mine Harada

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: Allogeneic hematopoietic stem cell transplantation (HSCT) for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is much more intensive than multi-agent combined chemotherapy, although allogeneic HSCT is associated with increased morbidity and mortality when compared with such chemotherapy. Minimal residual disease (MRD) status has been proven to be a strong prognostic factor for adult patients with Ph-negative ALL. Methods. We investigated whether MRD status in adult patients with ALL is useful to decide clinical indications for allogeneic HSCT. We prospectively monitored MRD after induction and consolidation therapy in adult patients with Ph-negative ALL. Results: Of 110 adult ALL patients enrolled between July 2002 and August 2008, 101 were eligible, including 59 Ph-negative patients. MRD status was assessed in 43 patients by the detection of major rearrangements in TCR and Ig and the presence of chimeric mRNA. Thirty-nine patients achieved CR1, and their probabilities of 3-year overall survival and disease-free survival (DFS) were 74% and 56%, respectively. Patients who were MRD-negative after induction therapy (n = 26) had a significantly better 3-year DFS compared with those who were MRD-positive (n = 13; 69% vs. 31%, p = 0.004). All of 3 patients who were MRD-positive following consolidation chemotherapy and did not undergo allogeneic HSCT, relapsed and died within 3 years after CR. Conclusions: These results indicate that MRD monitoring is useful for determining the clinical indications for allogeneic HSCT in the treatment of ALL in CR1.

Original languageEnglish
Article number14
JournalJournal of Hematology and Oncology
Volume6
Issue number1
DOIs
Publication statusPublished - Feb 8 2013

Fingerprint

Residual Neoplasm
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Prospective Studies
Hematopoietic Stem Cell Transplantation
Disease-Free Survival
Consolidation Chemotherapy
Drug Therapy
Philadelphia Chromosome
Therapeutics
Morbidity
Messenger RNA
Survival
Mortality

All Science Journal Classification (ASJC) codes

  • Hematology
  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL : Results of a prospective study (ALL MRD2002 Study). / Nagafuji, Koji; Miyamoto, Toshihiro; Eto, Tetsuya; Kamimura, Tomohiko; Taniguchi, Shuichi; Okamura, Takashi; Ohtsuka, Eiichi; Yoshida, Takashi; Higuchi, Masakazu; Yoshimoto, Goichi; Fujisaki, Tomoaki; Abe, Yasunobu; Takamatsu, Yasushi; Yokota, Shouhei; Akashi, Koichi; Harada, Mine.

In: Journal of Hematology and Oncology, Vol. 6, No. 1, 14, 08.02.2013.

Research output: Contribution to journalArticle

Nagafuji, K, Miyamoto, T, Eto, T, Kamimura, T, Taniguchi, S, Okamura, T, Ohtsuka, E, Yoshida, T, Higuchi, M, Yoshimoto, G, Fujisaki, T, Abe, Y, Takamatsu, Y, Yokota, S, Akashi, K & Harada, M 2013, 'Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: Results of a prospective study (ALL MRD2002 Study)', Journal of Hematology and Oncology, vol. 6, no. 1, 14. https://doi.org/10.1186/1756-8722-6-14
Nagafuji, Koji ; Miyamoto, Toshihiro ; Eto, Tetsuya ; Kamimura, Tomohiko ; Taniguchi, Shuichi ; Okamura, Takashi ; Ohtsuka, Eiichi ; Yoshida, Takashi ; Higuchi, Masakazu ; Yoshimoto, Goichi ; Fujisaki, Tomoaki ; Abe, Yasunobu ; Takamatsu, Yasushi ; Yokota, Shouhei ; Akashi, Koichi ; Harada, Mine. / Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL : Results of a prospective study (ALL MRD2002 Study). In: Journal of Hematology and Oncology. 2013 ; Vol. 6, No. 1.
@article{a165e62c1a5d41f18e0f0ca8e3af6ad1,
title = "Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: Results of a prospective study (ALL MRD2002 Study)",
abstract = "Background: Allogeneic hematopoietic stem cell transplantation (HSCT) for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is much more intensive than multi-agent combined chemotherapy, although allogeneic HSCT is associated with increased morbidity and mortality when compared with such chemotherapy. Minimal residual disease (MRD) status has been proven to be a strong prognostic factor for adult patients with Ph-negative ALL. Methods. We investigated whether MRD status in adult patients with ALL is useful to decide clinical indications for allogeneic HSCT. We prospectively monitored MRD after induction and consolidation therapy in adult patients with Ph-negative ALL. Results: Of 110 adult ALL patients enrolled between July 2002 and August 2008, 101 were eligible, including 59 Ph-negative patients. MRD status was assessed in 43 patients by the detection of major rearrangements in TCR and Ig and the presence of chimeric mRNA. Thirty-nine patients achieved CR1, and their probabilities of 3-year overall survival and disease-free survival (DFS) were 74{\%} and 56{\%}, respectively. Patients who were MRD-negative after induction therapy (n = 26) had a significantly better 3-year DFS compared with those who were MRD-positive (n = 13; 69{\%} vs. 31{\%}, p = 0.004). All of 3 patients who were MRD-positive following consolidation chemotherapy and did not undergo allogeneic HSCT, relapsed and died within 3 years after CR. Conclusions: These results indicate that MRD monitoring is useful for determining the clinical indications for allogeneic HSCT in the treatment of ALL in CR1.",
author = "Koji Nagafuji and Toshihiro Miyamoto and Tetsuya Eto and Tomohiko Kamimura and Shuichi Taniguchi and Takashi Okamura and Eiichi Ohtsuka and Takashi Yoshida and Masakazu Higuchi and Goichi Yoshimoto and Tomoaki Fujisaki and Yasunobu Abe and Yasushi Takamatsu and Shouhei Yokota and Koichi Akashi and Mine Harada",
year = "2013",
month = "2",
day = "8",
doi = "10.1186/1756-8722-6-14",
language = "English",
volume = "6",
journal = "Journal of Hematology and Oncology",
issn = "1756-8722",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL

T2 - Results of a prospective study (ALL MRD2002 Study)

AU - Nagafuji, Koji

AU - Miyamoto, Toshihiro

AU - Eto, Tetsuya

AU - Kamimura, Tomohiko

AU - Taniguchi, Shuichi

AU - Okamura, Takashi

AU - Ohtsuka, Eiichi

AU - Yoshida, Takashi

AU - Higuchi, Masakazu

AU - Yoshimoto, Goichi

AU - Fujisaki, Tomoaki

AU - Abe, Yasunobu

AU - Takamatsu, Yasushi

AU - Yokota, Shouhei

AU - Akashi, Koichi

AU - Harada, Mine

PY - 2013/2/8

Y1 - 2013/2/8

N2 - Background: Allogeneic hematopoietic stem cell transplantation (HSCT) for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is much more intensive than multi-agent combined chemotherapy, although allogeneic HSCT is associated with increased morbidity and mortality when compared with such chemotherapy. Minimal residual disease (MRD) status has been proven to be a strong prognostic factor for adult patients with Ph-negative ALL. Methods. We investigated whether MRD status in adult patients with ALL is useful to decide clinical indications for allogeneic HSCT. We prospectively monitored MRD after induction and consolidation therapy in adult patients with Ph-negative ALL. Results: Of 110 adult ALL patients enrolled between July 2002 and August 2008, 101 were eligible, including 59 Ph-negative patients. MRD status was assessed in 43 patients by the detection of major rearrangements in TCR and Ig and the presence of chimeric mRNA. Thirty-nine patients achieved CR1, and their probabilities of 3-year overall survival and disease-free survival (DFS) were 74% and 56%, respectively. Patients who were MRD-negative after induction therapy (n = 26) had a significantly better 3-year DFS compared with those who were MRD-positive (n = 13; 69% vs. 31%, p = 0.004). All of 3 patients who were MRD-positive following consolidation chemotherapy and did not undergo allogeneic HSCT, relapsed and died within 3 years after CR. Conclusions: These results indicate that MRD monitoring is useful for determining the clinical indications for allogeneic HSCT in the treatment of ALL in CR1.

AB - Background: Allogeneic hematopoietic stem cell transplantation (HSCT) for patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) in first complete remission (CR1) is much more intensive than multi-agent combined chemotherapy, although allogeneic HSCT is associated with increased morbidity and mortality when compared with such chemotherapy. Minimal residual disease (MRD) status has been proven to be a strong prognostic factor for adult patients with Ph-negative ALL. Methods. We investigated whether MRD status in adult patients with ALL is useful to decide clinical indications for allogeneic HSCT. We prospectively monitored MRD after induction and consolidation therapy in adult patients with Ph-negative ALL. Results: Of 110 adult ALL patients enrolled between July 2002 and August 2008, 101 were eligible, including 59 Ph-negative patients. MRD status was assessed in 43 patients by the detection of major rearrangements in TCR and Ig and the presence of chimeric mRNA. Thirty-nine patients achieved CR1, and their probabilities of 3-year overall survival and disease-free survival (DFS) were 74% and 56%, respectively. Patients who were MRD-negative after induction therapy (n = 26) had a significantly better 3-year DFS compared with those who were MRD-positive (n = 13; 69% vs. 31%, p = 0.004). All of 3 patients who were MRD-positive following consolidation chemotherapy and did not undergo allogeneic HSCT, relapsed and died within 3 years after CR. Conclusions: These results indicate that MRD monitoring is useful for determining the clinical indications for allogeneic HSCT in the treatment of ALL in CR1.

UR - http://www.scopus.com/inward/record.url?scp=84873255438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873255438&partnerID=8YFLogxK

U2 - 10.1186/1756-8722-6-14

DO - 10.1186/1756-8722-6-14

M3 - Article

VL - 6

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

SN - 1756-8722

IS - 1

M1 - 14

ER -